Last updated
Thermo Fisher Scientific: Geographic Expansion
Thermo Fisher Scientific's Manila Shared Services Centre is scaling rapidly from 100 to ~700 employees by 2026, positioning itself as a high-impact regional hub for Asia-Pacific operations with focus on digital transformation and strategic value creation beyond cost efficiency.
Source: HRM Asia
- Who
- Thermo Fisher Scientific · Biotech & Pharma · Asia
- What happened
- Thermo Fisher Scientific's Manila Shared Services Centre is scaling rapidly from 100 to ~700 employees by 2026, positioning itself as a high-impact regional hub for Asia-Pacific operations with focus on digital transformation and strategic value creation beyond cost efficiency.
- When
- 2026-06-04
- Source
- HRM Asia
- So what
- The Manila centre's expansion from 100 to roughly 700 employees commits Thermo Fisher to an operating model it did not have at launch: a site large enough to absorb genuine business-process ownership, not just transactional throughput.
The leadership read
The Manila centre's expansion from 100 to roughly 700 employees commits Thermo Fisher to an operating model it did not have at launch: a site large enough to absorb genuine business-process ownership, not just transactional throughput. At that headcount, the centre crosses the threshold where it can hold end-to-end accountability for reporting cycles, decision-support analytics, and process-improvement governance, functions that require embedded domain knowledge, not interchangeable labour. The explicit framing around AI-augmented workflows and OpenAI collaboration means the site is simultaneously scaling human capacity and compressing the transactional work that would have justified that headcount under the old GBS logic. That tension, more people, less repetitive work, is the operational problem the site now has to solve through role design. This is one of twelve geographic expansion signals we have tracked across Asia-Pacific and adjacent corridors in the last 90 days. The pattern is heterogeneous in sector. Sarvam entering the US, Mitsubishi Electric committing $30M to Ohio manufacturing, India exporting digital public infrastructure to 24 nations, but a consistent thread runs through the technology-services subset: footprint decisions being made simultaneously with capability-repositioning decisions, not sequentially. Companies reaching this stage of GBS scaling in Southeast Asia face rising demand for leadership at the intersection of process-intelligence and people operations, specifically, those who can manage the redesign of work architecture as automation absorbs execution tasks, alongside change-management capability sophisticated enough to hold engagement through that transition. The market is moving toward operators who can run analytics-enabled service delivery while maintaining the talent development infrastructure that prevents high-attrition hollowing at scale.
Market context: This lands while the Talent Market Index reads 109 (Hot) — up 7.3 versus the prior month — and Asia signal share is rising (+2.7pts).
Thermo Fisher Scientific: 1 signal in the last 90 days — in line with the Biotech & Pharma median of 1 across 33 tracked companies; 0.1% of MitchelLake's Asia signal flow; 4 tracked across 175 days.
Market entry — the MitchelLake playbook
When a company expands into a new market, the first leadership hires decide whether it lands. A selection of market entries we've run:
All market-entry case studies →MitchelLake in this thematic
Also at Thermo Fisher Scientific →
More signals across Biotech & Pharma
Geographic Expansion · Asia
Gilead Sciences →Gilead is reportedly turning to an executive from BeOne to support its China expansion, signalling a push into the Chinese market.
Geographic Expansion · Asia
Promomed Group →Promomed Group (Russian pharmaceutical company) is expanding into Vietnam's pharmaceutical market with strategic partnerships. Founder Petr Bely met with Vietnam's Minister of Health to discuss long-term cooperation, technology transfer, and manufacturing operations targeting innovative drugs, biosimilars, and monoclonal antibodies
Partnership · Asia
Bora Pharmaceuticals →Bora Pharmaceuticals signed partnership with Insilico Medicine for AI drug discovery. Company launched group-wide AI in Manufacturing program (BORA AIM) to improve process efficiency across sites.
Product Launch · Asia
Biogen →Biogen's monoclonal antibody felzartamab received first global approval in China for second-line multiple myeloma treatment, in combination with lenalidomide and dexamethasone.
Product Launch · Asia
Celltrion →Celltrion achieved record quarterly earnings (1.4 trillion won / $950M in sales, 451.8B won operating profit) driven by growing sales of newer biosimilar portfolio and improved manufacturing efficiency. YoY sales growth of 45% and operating profit growth of 86.3%.
Product Launch · Asia
Bristol Myers Squibb →Bristol Myers Squibb launched Relopduo, a fixed-dose combination dermatology-cancer drug, in India. The drug received USFDA approval in 2022 and is now being commercialized in the Indian market.
Where this lands in our work
- Cross Border Expansion Executive Search →
The peak executive-hiring window opens 12–18 months after an expansion commitment.
- Executive Search: Asia →
Our Asia practice runs the searches behind signals like this one.
Intelligence powered by Autonodal ↗
